Découvrez ci-dessous la liste complète de nos communiqués de presse (page 3 sur 28) :
AMX0035, designated as an orphan drug, improves glycaemic control and vision in Wolfram syndrome patients.
JAMP Pharma recalls digoxin pills for potential misdosing. Patients should consult their pharmacist immediately.
CDSCO and SDCs enforce drug quality laws, inspecting 400 facilities and taking over 300 actions against violations.
FDA grants fast-tracked approval to Tecelra for treating synovial sarcoma, marking a key milestone for Adaptimmune.
Zevra Therapeutics gets FDA GeMDAC's backing (11-5) on arimoclomol for Niemann-Pick disease type C. FDA decision due by September 21, 2024.
SCHOTT Pharma unveils a 160-syringe nest for prefillable syringes, boosting efficiency by 67%, cutting costs, and reducing carbon footprint by 17%.
Freudenberg Medical Expands Biopharma Line with Custom Single-Use Assemblies for Protein Production and Bioprocessing.
Sanofi plans to invest €1.3bn in a new insulin facility in Frankfurt by 2029, supported by German government initiatives to strengthen pharma production.
PA Governor invests $3M in Adare Pharma's $16.8M expansion, creating 115 jobs, relocating HQ to Philly, and boosting the state's life sciences hub.
Vietnam's $7B pharmaceutical market faces infrastructure and financial challenges, yet shows 7.3% annual growth, aiming to be a regional hub by 2030.
Dr. Jaideep Gogtay of Cipla highlights the urgent need for enhanced surveillance and drug discovery to combat Antimicrobial Resistance (AMR) in India.
Court dismisses drug manufacturers' IRA price-setting challenges; Novo Nordisk plans appeal, others continue objections.
UP Manila develops E-Tox POCT kits for detecting poisoning drugs and NPS, filling a critical emergency need.
CordenPharma invests €900M ($981M) to boost GLP-1 peptide manufacturing in Europe and the US, aiming for €1B sales by 2028. Largest investment in 18 years.
Attendees experienced a heartfelt documentary that honoured Dr. KH Sancheti's journey, highlighting his commitment to affordable healthcare and patient care.
Ono Pharmaceutical partners with Monash University to develop new anti-GPCR antibodies, aiming to create treatments for autoimmune and inflammatory diseases.
Eli Lilly and Novo Nordisk race to meet high demand for GLP-1 weight-loss drugs, aiming to supply a market projected to reach $150 billion by the early 2030s.
DKSH partners with Kyowa Kirin to enhance healthcare access across Asia-Pacific, promoting established medicines and driving sustainable growth in the region.
FDA accepts LK's JLK-CTP application. Korean AI firm aggressively pursuing U.S. market for stroke diagnostic solutions.
Formosa Pharma partners with Apotex to market APP13007 in Canada for post-op eye inflammation relief.
Kakao Healthcare's research alliance with top hospitals aims to revolutionize global healthcare through AI and big data.
Destiny Pharma to present data at IPS 2024 showing XF-73 reduces MRSA in burn wounds by 99.99% and prevents sepsis, a breakthrough in infection control.
Biotech startup Ribon Therapeutics ceased operations in 2024, auctioning its assets, including PARP inhibitors.
Rznomics and SK pharmteco sign a multi-year MOU to develop and market RNA-based gene therapy products.
Agenus regains AGEN1777 after Bristol Myers cancels a $1B cancer immunotherapy deal amid strategic realignment.
BioMarin refocuses ROCTAVIAN® on the U.S., Germany, and Italy, cutting costs to $60M by 2025 for severe hemophilia A.
Asymchem opens a new European facility in Kent, U.K., to boost R&D and manufacturing with advanced, sustainable technologies.
The FDA rejects Telix Pharmaceuticals' TLX250-CDx PET imaging agent for kidney cancer due to sterility concerns, though approval is still anticipated.
WCG acquires Array to enhance clinical research training, improving efficiency, safety, and outcomes through innovative engagement and data insights.
Lantern Pharma's AI-driven HARMONIC™ phase 2 trial of LP-300 with chemotherapy shows promising safety and efficacy in NSCLC patients post-TKI treatment.
Yaskawa and Astellas partner to enhance cell therapy production, bridging research to commercialization efficiently.
Quoin Pharmaceuticals starts a New Zealand trial for QRX003, aiming to treat Peeling Skin Syndrome in children.
Lupin's Phase 3 trial of LUBT010, a biosimilar to Lucentis, shows therapeutic equivalency in treating wet AMD.
Celltrion's Zymfentra, a subcutaneous infliximab, joins major US PBM insurance lists after March launch.
CereMark Pharma's Phase III trial will investigate F-18 flornaptitril, targeting proteins in Alzheimer's and CTE.
Henrietta Lacks' family sues Novartis and Viatris for profiting from HeLa cells taken without consent in 1951, seeking justice and restitution.
Cloudbreak Pharma partners with Santen Pharmaceutical to develop CBT-001 in Southeast Asia, while preparing for a Hong Kong listing amid rising losses.
Sangamo and Genentech collaborate on gene therapies for neurological diseases, aiming to tackle conditions like Alzheimer's.
Reviva Pharmaceuticals secures USPTO patent for brilaroxazine, enhancing IP for treating lung diseases including IPF and COPD.
Daiichi Sankyo and Merck expand global partnership to develop MK-6070, a DLL3-targeting therapy for neuroendocrine tumors and SCLC.
Nestlé Health Science acquires Seres' VOWST, funding Seres' pipeline and improving outcomes for fragile patient groups.
NeuroBo Pharmaceuticals, partnering with Dong-A ST and ImmunoForge, is developing a long-acting, once-monthly version of DA-1726, targeting obesity treatment.
Tonix Pharmaceuticals announces a new publication on COVID-19 convalescent sera screening in "Microorganisms," highlighting their advanced imaging technology.
Compass Therapeutics enrolls 150 patients in the COMPANION-002 trial to assess CTX-009 for BTC. New IST approved at MD Anderson for first-line treatment.
Cadrenal Therapeutics is in talks with Abbott for a tecarfarin study in LVAD patients, aiming to enhance anticoagulation and prevent strokes.
Roche, Chugai sign agreement for RG6631, an anti-TL1A antibody for Crohn's and ulcerative colitis treatment in Japan.
WHO alert, Counterfeit Oxymorphone Hydrochloride 40mg tablets found in Finland. Contains dangerous metonitazene, report adverse effects to authorities.
Shanton Pharma has completed enrollment for its Phase 2b trial of SAP-001, targeting refractory gout patients, with topline data expected in Q1 2025.
Aurobindo Pharma Receives USFDA Approval for Estradiol Inserts, Reaches 521 ANDA Approvals, Reports 79.5% Profit Increase in Q4 FY24.
Vertex, NHS England provide gene therapy for beta thalassaemia; CASGEVY approved by UK MHRA and NICE.
FDA approves Purdue Pharma's Zurnai auto-injector for opioid overdose, treating adults and children 12+.
Formosa and Eyenovia team up to develop Clobetasol Propionate for dry eye, leveraging advanced nanoparticle technology.
Pharmacosmos acquires G1 Therapeutics for $405M, enhancing COSELA's reach for lung cancer patients, benefiting stakeholders.
Abbott and Medtronic team up to create an integrated CGM system, enhancing diabetes management with automated insulin delivery.
Adial Pharmaceuticals completes dosing for AD04 study targeting Alcohol Use Disorder, with top-line results expected in Q4 2024.
Agenus Inc. unveils a study on botensilimab, a novel anti-CTLA-4 antibody, showing efficacy in resistant cancers, transforming the tumor microenvironment.
Silo Pharma partners with WuXi AppTec to study SPU-16 peptide for MS treatment, leveraging CNS targeting for enhanced drug delivery and reduced toxicity.
Lonza boosts Bend, Oregon facility for clinical bottling, enhancing early-phase trial efficiency and product delivery.
Mallinckrodt launches the Acthar Gel SelfJect™ Injector, a user-friendly option for patients with chronic inflammatory and autoimmune conditions.
Samsung Biologics becomes the first Korean CDMO to join the PSCI, committing to sustainable practices and enhancing its ESG efforts in global healthcare.
CVC Capital Partners agrees to acquire Mallinckrodt's Therakos division for $925 million, aiming to enhance its global reach in immune-related therapies.
FDA approves CREXONT, a new CD/LD formulation for Parkinson's, offering longer "Good On" time with fewer doses.
Conduit Pharmaceuticals and AstraZeneca partner to advance AZD5904, AZD1656, and AZD5658 for autoimmune diseases and infertility in Phase II trials.
Iris Acquisition Corp is progressing with its merger plans with Liminatus Pharma, filing an amended Form S-4 and securing a Nasdaq listing extension.
Merck terminates Phase 3 KeyVibe-008 trial for small cell lung cancer due to failure to meet survival endpoints and increased adverse events.
Apellis Pharmaceuticals and Sobi reveal promising Phase 3 VALIANT study results, showing pegcetacoplan's potential for C3G and IC-MPGN.
USSF invests $15M to expand its Lehigh Valley biopharma facility, boosting clean room capacity and creating 100+ jobs, enhancing its pharmaceutical services.
Merck acquires CN201 for $700M with up to $600M in milestones, targeting B-cell disorders; closing in Q3 2024.
FDA approves Neffy, the first needle-free epinephrine for severe allergies, improving patient care and outcomes.
Vivint Pharma invests $48M in Hyderabad facility, creating 1,000 jobs to produce injectables for critical care and cancer.
Angiex begins Phase 1 trial dosing for AGX101, an innovative TM4SF1-directed ADC targeting solid tumors.
Novartis' Fabhalta gets FDA approval for IgAN, targeting complement system to reduce proteinuria in kidney disease.
Meiji Seika Pharma Co., Ltd. opens a new Boston office, its venture into life sciences investments to develop innovative therapies for global health needs.
Oncimmune wins $1.5M contract with major pharma, expects FY24 revenue of £3.0M and profitability by FY25.
Granules India secures FDA approval for trazodone tablets, enters $128M U.S. market with expected strong growth.
India's pharma industry highlights HVAC's vital role in ensuring product quality, worker safety, and regulatory compliance.
LTS and GRAMME team up to provide pharma firms with turnkey solutions for biologic drug delivery and market access.
FDA charges BMS with fabricating data on Krazati's effectiveness for KRAS cancer, challenging trial findings.
Recursion buys Exscientia for $688M, expanding AI-based drug development pipeline and forming new pharma alliances.
Merck's Aarogya program, launched in Patalganga, Raigad, offers health screenings, diagnostics, and awareness, impacting 800+ lives with comprehensive care.
Chifu and CTC BIO sign exclusive deal to distribute One-two Tab in Taiwan, with plans for global expansion.
GC MS signs a $2.9M export deal with Hong Kong's Firstlink Healthcare for Gcare Lipid devices, expanding its global reach in diagnostic technology.
Tobinco Pharmaceuticals cleared by Accra High Court, FDA allegations of counterfeit drug importation dismissed. Legal victory announced August 2024.
FDA issues CRL for Lykos Therapeutics' PTSD drug, citing safety concerns; requests more Phase III trials.
Atul Bioscience receives FDA EIR for Ambernath plant, with zero findings after successful May 2024 inspection.
GC Biopharma's GC1130A for Sanfilippo syndrome gets Japan PMDA approval for phase 1 trial, following U.S. and Korea approvals.
Marker Therapeutics receives $2M NIH grant to study MT-601 for relapsed non-Hodgkin's lymphoma post CAR-T therapy.
LENZ Therapeutics files NDA with FDA for LNZ100, showing promise in Phase 3 for presbyopia treatment.
Wave Life Sciences' WVE-N531, targeting Duchenne muscular dystrophy, receives FDA Rare Pediatric Disease designation.
Breas Medical recalls 8,186 Vivo 45 LS ventilators due to potential formaldehyde exposure, impacting units distributed between Feb 2021 and July 2024.
Pneuma Systems' PneumaFlow Controller joins the FDA's Safer Technologies Program, enhancing infusion safety and streamlining patient care.
60 Degrees Pharma grants the University of Kentucky FDA reference rights for ARAKODA®, advancing a Phase IIb study on malaria treatment with SJ733.
Ascendis Pharma's YORVIPATH gains FDA approval for hypoparathyroidism, offering a once-daily treatment option for patients.
Syros Pharmaceuticals halts patient enrollment in SELECT-AML-1 Phase 2 trial after interim results show no superiority of triplet therapy for AML treatment.
Astria Therapeutics Partners with Ypsomed to Develop Autoinjector for STAR-0215, Offering Patients Flexible, Low-Burden Administration Options.
Daiichi Sankyo's ENHERTU® gains conditional approval in China for advanced HER2+ gastric/GEJ adenocarcinoma.
Blue Earth Therapeutics expands its partnership with Seibersdorf Labor to produce 225Ac-based radioligand therapy for clinical trials in the UK, EU, and U.S.
Taiwan Bio Therapeutics and TRACT Therapeutics advance TregCel technology transfer, setting the stage for a global Phase 2 trial in kidney transplant patients.
Celltrion's Yuflyma biosimilar is now available at Costco, offering uninsured members significant discounts on this crucial medication for chronic conditions.
CMS assigns Abeona's pz-cel gene therapy a specific procedure code, enhancing hospital billing and reimbursement for RDEB.
Florida's Grant Cancer Centre first in U.S. to use Accuray Radixact® System with VitalHoldTM, boosting cancer treatment precision.
NeuroBo completes enrollment for Phase 1 trial of DA-1726, a dual agonist for obesity with superior pre-clinical results.
Boudicca Dx and Adial partner to develop a companion diagnostic for AD04, a precision treatment for alcohol use disorder.
Kiromic's KB-GDT-01 (Deltacel) therapy shows promising PFS results in NSCLC patients in the Deltacel-01 trial, with no dose-limiting toxicities observed.
Galderma's Nemluvio receives FDA clearance for prurigo nodularis, aiming to ease severe itching and skin nodules. Blockbuster potential in dermatology.
Baxter shifts strategy by planning to sell Vantive to Carlyle, aiming to enhance shareholder value and focus on growth, marking a pivotal transformation.
Medtronic's brain modulation division reports low double-digit growth, boosted by Percept RC demand and new asleep DBS approval, enhancing its competitive edge.
Rivus' HU6 shows promise in Phase 2a trial for obesity-related heart failure, achieving key weight loss goals.
Kerato partners with the University of Montreal to develop an innovative corneal treatment, aiming to simplify procedures and improve patient outcomes.
Medison Pharma expands its collaboration with Alnylam Pharmaceuticals to enhance access to RNAi therapies across Central and Eastern Europe, Israel, and more.
Alera Pharma, Lobe Sciences’ US subsidiary, focuses on neurology, merging with the Australian branch soon.
AstraZeneca's sBLA for Imfinzi in LS-SCLC has been accepted by the FDA with Priority Review, backed by the ADRIATIC trial's positive survival results.
Nanoform and Takeda partner to develop plasma-derived therapies for rare diseases. Non-GMP nanomaterials will help advance formulations to market by 2025.
Hoth Therapeutics teams with Aronnax to advance HT-KIT, an FDA Orphan Drug for mast cell cancers, refining dosing and trial protocols.
Gilead's Livdelzi (seladelpar) wins FDA accelerated approval for primary biliary cholangitis, showing notable reductions in ALP levels and pruritus.
FDA recalls B. Braun and Baxter sodium chloride batches due to endotoxins, particle leaks, and contamination risks.
Medtronic partners with Abbott to integrate CGM tech into insulin pumps, aiming to revive diabetes care segment.
Cuban-China joint venture prepares China trials for Itolizumab, tech transfer for cancer drugs, and R&D projects.
Abbott's AVEIR DR system enables Canada's first dual chamber leadless pacemaker implants for better heart rhythm care.
Uzbekistan and AstraZeneca explore partnership opportunities for expanding pharmaceutical production and investment.
FDA issues a warning to Aurobindo Pharma's unit after inspection; shares dip amid compliance concerns.
NMPA approves marketing change for Baiyunshan’s Pseudoephedrine and Paracetamol products, boosting its portfolio.
Eli Lilly acquires Morphic Holding to enhance its IBD treatment options with innovative oral integrin therapies.
Bavarian Nordic's Imvanex mpox vaccine seeks EMA approval for teen use, backed by successful Phase II trials.
Sanyou Biopharmaceuticals launches AI-powered oneClick+ platform to accelerate antibody development with advanced design tools and automated analysis.
Novo Nordisk invests 1.5 billion DKK in a Køge facility to boost GLP-1 drug production, marking a key step in their global expansion strategy.
IMBiologics transfers autoimmune tech to Huadong Pharmaceutical in a deal worth up to $375M. Huadong gains rights to develop in Asia, excluding key markets.
NorthStar and Convergent are advancing prostate cancer treatment with CONV01-α, using Ac-225 and a monoclonal antibody.
Nuntius and Taiho partner to boost mRNA cancer therapy with advanced nanocarrier tech. Financials undisclosed.
Hikma Pharmaceuticals extends KLOXXADO® nasal spray’s shelf life to 36 months, doubling naloxone dose per spray.
Inspira Technologies secures AMAR approval for its INSPIRA ART100, advancing extracorporeal membrane oxygenation and cardiopulmonary bypass solutions globally.
SciSparc secures exclusive rights to develop SCI-160 pain therapy, with potential $6M+ in earnings and milestone fees.
Huawei’s Watch D2, now medically certified in China, features advanced blood pressure monitoring. Release and price details are still pending.
Avantor divests clinical services to Audax for $650M to focus on lab and production growth, per CEO Michael Stubblefield.
Dr Reddy’s close to buying Nicotinell from Haleon in a deal worth hundreds of millions, aiming for EU market growth.
Discover advanced cleanroom solutions at CPHI & PMEC India 2024. Explore innovations in modular cleanrooms, HVAC systems, and contamination control.
Control Bionics' NeuroNode gets CMS approval with HCPCS code E2513, securing $4,300 reimbursement and aiding users with severe movement impairments.
Alembic Pharmaceuticals gains USFDA approval for Dabigatran Etexilate Capsules, 110 mg, boosting its ANDA total to 211.
Opaganib reduces HFD-induced weight gain and glucose intolerance, targeting a new pathway for obesity treatment.
EMA review of Breyanzi for relapsed/refractory FL could extend CAR T therapy benefits to high-risk lymphoma patients.
Daewoong's NUCEIVA® Botulinum Toxin Launches in Australia at Aesthetics 2024, Marking Global Expansion and New Opportunities in Aesthetic Treatments.
Tanvex BioPharma USA, Inc. secures FDA approval for NYPOZI™ and BLA acceptance for TX-05, advancing biosimilar innovation for cancer treatment.
FDA lifts partial hold on MediLink's BNT326/YL202 Phase I trial, resuming recruitment with new safety measures and updated protocols.
Visiox Pharmaceuticals merges with Ocuvex Therapeutics to enhance eye care leadership, expanding their product range and market impact.
Oncimmune lands a $1.5M contract to profile IgE autoantibodies, expanding its global pharma partnership. Revenue expected in FY 2025.
Germany faces drug shortages as states halt China inspections due to new espionage laws, risking supply chain disruptions in Europe.
Hyundai Pharm launches Slinda in South Korea through an exclusive deal with ASKA Pharmaceutical, offering a new progestin-only contraceptive option.
Nightingale Health secures additional HSA approval in Singapore for expanded blood tests including fatty acids analysis.
ZOLL® wins bid for Vyaire Medical’s ventilator business, pending court approval, enhancing its respiratory care portfolio.
Regeneron receives CRL for linvoseltamab in R/R MM, awaiting FDA re-inspection after manufacturing concerns.
Marksans Pharma's Goa plant receives EIR from USFDA, inspection classified as Voluntary Action Indicated (VAI).
Granules Pharma’s ANDA for Glycopyrrolate Oral Solution 1mg/5mL, bioequivalent to Cuvposa, accepted by FDA.
Fujifilm Diosynth Biotechnologies expands its facility, tripling production capacity to support specialized treatment for wet age-related macular degeneration.
VGXI Inc. joins the BioMap Consortium, enhancing U.S. biopharmaceutical production with its extensive expertise and leading plasmid DNA capacity.
eXmoor Pharma gains MHRA licence for GMP-grade cell and gene therapies at its new Bristol facility, marking a key milestone in its global expansion
Delhi High Court rules that trademark laws apply to corporate names, overturning Mankind Pharma's case dismissal against Mercykind Pharmaceuticals.
IGC Pharma’s AI suggests IGC-1A may be a GLP-1 agonist, offering growth potential in Alzheimer’s and weight loss markets.
BerGenBio teams with Tempus to advance bemcentinib for NSCLC, leveraging AI for data-driven insights and synthetic controls.
Bora Pharmaceuticals has finalized the acquisition of Emergent BioSolutions' 87,000 sq. ft. sterile manufacturing facility in Camden, Maryland, enhancing its U.S. presence and capabilities in aseptic fill/finish services.
Sigachi Industries launches PureCoat and UltraMod, revolutionary pharmaceutical coatings designed to enhance drug stability, delivery, and bioavailability.
PCI Pharma Services becomes the first CDMO to pass the ICMRA's Collaborative Hybrid Inspection Pilot program at its Bedford, NH site, streamlining global regulatory approvals.
Benuvia to source DEA-approved cannabis and psychedelics from Bright Green for cGMP pharmaceutical APIs.
Touchlight and Nottingham University collaborate on scalable DNA vaccine for Zika, backed by UK Vaccine Network.
Vantedge Medical, backed by Aterian, acquires precision device maker Hobson & Motzer to expand in surgical staplers and enhance manufacturing for top OEMs.
SI-Bone’s TNT Implant earns FDA clearance, offering enhanced fixation and reduced screw backout for pelvic fractures. Designed for sacropelvic anatomy.
Amplitude Vascular Systems partners with Jacobs Institute to test Pulse IVL system for improved coronary and carotid artery treatments and stroke care.
TNF Pharmaceuticals to begin mid-stage trials for MYMD-1, targeting sarcopenia and expanding into autoimmune conditions.
RedHill Biopharma launches Talicia in the UAE to treat H. pylori infections, marking the region’s first low-dose rifabutin therapy.
Tris Pharma initiates Phase 3 trials for cebranopadol, designed to provide opioid-level pain relief with less addiction risk.
ST Pharm signs deal with Gilead, driven by US biosecurity measures, to supply APIs for blockbuster HIV drug Biktarvy.
Troy M. Wagner named VP of Quality Assurance at Tempest Therapeutics, focusing on late-stage oncology candidate amezalpat.
Leo Pharma’s TMB-001 for congenital ichthyosis fails Phase III trial, missing key goals, halting FDA submission plans.
Innocan Pharma’s subsidiary achieves MoCRA compliance, advancing plans for premium cosmetics in the US market.
eXmoor Pharma earns MHRA approval, enabling GMP manufacturing of cell and gene therapies for clinical trials in the UK.
Novartis and Versant launch Borealis Biosciences, advancing kidney disease research with xRNA-based innovations in Canada.
Bridge Biotherapeutics partners with HitGen to fast-track the discovery of novel anticancer drugs, leveraging HitGen's DNA-encoded library technology.
Samjin Pharmaceuticals donates Geworin to underserved communities and disaster zones, boosting global healthcare efforts.
UK approves Leqembi for early-stage Alzheimer’s, but NHS access denied due to high costs and uncertainty over long-term effectiveness.
The FDA is launching a new surveillance system to better track risks of defective medical devices, aiming to prevent injuries and deaths. Launch by Dec 2024.
Alkem MedTech partners with Exactech to manufacture and market joint implants in India, boosting local production and expanding orthopedic access.
PharmaTech Expo 2024 returns in Gujarat, emphasizing pharmaceutical advancements and industry collaboration.
DuPont strengthens medical device capabilities with acquisitions of Donatelle and Spectrum Plastics, enhancing growth.
VION acquires Echelon Biosciences, boosting lipid-based excipients for mRNA therapies and expanding product offerings.
OKYO Pharma’s OK-101 shows promise in Phase 2 trials for dry eye and corneal pain, addressing unmet medical needs.
Altamira expands Bentrio® distribution to Sweden and Denmark via Pharma Nordic, following success in Norway’s market.
Eli Lilly extends partnership with Oblique Therapeutics to discover a second antibody using AbiProt’s epitope technology.
Ingenza and Cellugy team up to advance bacterial cellulose production for bio-based alternatives to petrochemicals.
India’s BioE3 Policy aims to drive biotech growth, innovation, and biomanufacturing jobs through green economy models.
BioIVT acquires ZenBio to enhance biospecimen offerings, expand cell services, and boost support for pharma and cosmetics R&D.
LBT Innovations upgrades APAS® Independence to support 55mm plates, boosting pharmaceutical environmental monitoring capabilities.
Alembic Pharma gets USFDA approval for Betamethasone Valerate Foam, 0.12% for scalp dermatoses. Total 213 ANDAs approved.
Innocan Pharma’s BI Sky Global achieves FDA MoCRA registration, meeting high standards for U.S. cosmetic products.
PPPI aims to partner with PhilHealth to secure medicine supplies for Konsulta and GAMOT programs, with new Botika ng Bayan for distribution.
Orchid Pharma and Cipla launch Cefepime-Enmetazobactam for cUTI, HAP, and VAP, boosting AMR efforts and nationwide distribution in India.
Siemens Healthineers buys Novartis’ AAA diagnostics unit for €200M, enhancing PET scan imaging and market reach.
SurGenTec’s FDA-approved B-MAN Kit enhances bone marrow aspiration with CELLect tech for optimal, contaminant-free results.
The Union Cabinet approves BioE3 policy, boosting India's biomanufacturing with a focus on innovation, sustainability, and net zero emissions by 2070.
Tonix Pharmaceuticals and Bilthoven Biologicals team up to advance TNX-801, a promising mpox vaccine candidate, showing strong preclinical results.
Sana Biotechnology names Dr. Dhaval Patel as EVP & CSO, advancing clinical programs and Type 1 diabetes trials, with a stock target increase.
Regeneron's Ordspono gets EU nod for relapsed or refractory follicular lymphoma and DLBCL, marking its first bispecific.